DRD2 and Parkinson disease: Sumanirole was chosen as it shows 200-fold more selectivity for D2R than for other DA receptors subtypes and as it has been used both in human patients and animal models of PD (McCall et al., 2005; Stephenson et al., 2005; Barone et al., 2007).